1-3 of 3
Bernhard Hauns
Close
Sort by
Journal Articles

Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATE TM Study

Christian Buske, MD, Alessandra Tedeschi, MD, Judith Trotman, MBChB, FRACP, FRCPA, Ramón García-Sanz, MD PhD, David MacDonald, MD, Veronique Leblond, MD PhD, Béatrice Mahé, MD, Charles Herbaux, MD, Jeffrey V. Matous, MD, Constantine S. Tam, MD, Leonard T. Heffner, MD, Marzia Varettoni, M. Lia Palomba, MD, Chaim Shustik, MD, Efstathios Kastritis, MD, Steven P. Treon, MD PhD, Jerry Ping, PhD, Bernhard Hauns, MD PhD, Israel Arango-Hisijara, MD, Meletios A Dimopoulos
Journal: Blood
Blood (2020) 136 (Supplement 1): 24–26.
https://doi.org/10.1182/blood-2020-134460
Published: 2020
Journal Articles

Final Results of the Phase II SAPHIRE Trial of Resminostat (4SC-201) in Patients with Relapsed/Refractory Hodgkin Lymphoma

Jan Walewski, MD, PhD, Ewa Paszkiewicz-Kozik, Agnieszka Warszewska, Gabriela Borsaru, Andreea Moicean, Andrzej Hellmann, Jiri Mayer, MD, PhD, Bernhard Hauns, Anna Mais, Stefan W. Henning, Bernd Hentsch
Journal: Blood
Blood (2011) 118 (21): 2675.
https://doi.org/10.1182/blood.V118.21.2675.2675
Published: 2011
Journal Articles

Resminostat In Relapsed or Refractory Hodgkin Lymphoma: Initial Results of the SAPHIRE Phase II Trial with a Novel Oral Histone Deacetylase (HDAC) Inhibitor.

Jan Walewski, MD, PhD, DSc, Ewa Paszkiewicz-Kozik, MD, Gabriela Borsaru, MD, Andreea Moicean, MD, Agnieszka Warszewska, MD, Klaus Strobel, MD, Alberto Biggi, MD, Bernhard Hauns, MD, Anna Mais, PhD, MSc, Stefan W. Henning, PhD, MSc, Bernd Hentsch, PhD
Journal: Blood
Blood (2010) 116 (21): 2811.
https://doi.org/10.1182/blood.V116.21.2811.2811
Published: 2010